Rijksuniversiteit Groningen has identified histone deacetylase (HDAC) inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, small cell and non-small-cell lung cancer (NSCLC).